Anti-platelets in diabetes management

N. M. Grantham, D. J. Magliano, G. Tai, N. Cohen, J. E. Shaw

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy, but only 7.1% of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.

Original languageEnglish
Pages (from-to)458-462
Number of pages5
JournalInternal Medicine Journal
Issue number6
Publication statusPublished - Jun 2010
Externally publishedYes


  • Aspirin
  • Cardiovascular disease
  • Complications
  • Diabetes mellitus
  • Prevention and control
  • Type 2

Cite this